XFOR logo

X4 Pharmaceuticals (XFOR)

Profile

Full Name

X4 Pharmaceuticals, Inc.

Ticker Symbol

XFOR

Exchange

NASDAQ

Country

United States

IPO

November 16, 2017

Indexes

Not included

Employees

143

Key Details

Price

$0.20(-1.59%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$2.56M

Annual EPS

-$0.19(+66.67% YoY)

PE ratio

-

Next earnings date

May 7, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Mar 27, 25 HC Wainwright & Co.
Buy
Mar 26, 25 Cantor Fitzgerald
Overweight
Feb 7, 25 HC Wainwright & Co.
Buy
Jan 14, 25 HC Wainwright & Co.
Buy
Nov 14, 24 Stifel
Buy
Nov 14, 24 HC Wainwright & Co.
Buy
Jun 28, 24 HC Wainwright & Co.
Buy
May 31, 24 Cantor Fitzgerald
Overweight
Apr 30, 24 HC Wainwright & Co.
Buy
Mar 22, 24 HC Wainwright & Co.
Buy

Institutional Ownership

  • What is the ticker symbol for X4 Pharmaceuticals?
  • Does X4 Pharmaceuticals pay dividends?
  • What sector is X4 Pharmaceuticals in?
  • What industry is X4 Pharmaceuticals in?
  • What country is X4 Pharmaceuticals based in?
  • When did X4 Pharmaceuticals go public?
  • Is X4 Pharmaceuticals in the S&P 500?
  • Is X4 Pharmaceuticals in the NASDAQ 100?
  • Is X4 Pharmaceuticals in the Dow Jones?
  • When was X4 Pharmaceuticals's last earnings report?
  • When does X4 Pharmaceuticals report earnings?
  • Should I buy X4 Pharmaceuticals stock now?

What is the ticker symbol for X4 Pharmaceuticals?

The ticker symbol for X4 Pharmaceuticals is NASDAQ:XFOR

Does X4 Pharmaceuticals pay dividends?

No, X4 Pharmaceuticals does not pay dividends

What sector is X4 Pharmaceuticals in?

X4 Pharmaceuticals is in the Healthcare sector

What industry is X4 Pharmaceuticals in?

X4 Pharmaceuticals is in the Biotechnology industry

What country is X4 Pharmaceuticals based in?

X4 Pharmaceuticals is headquartered in United States

When did X4 Pharmaceuticals go public?

X4 Pharmaceuticals's initial public offering (IPO) was on November 16, 2017

Is X4 Pharmaceuticals in the S&P 500?

No, X4 Pharmaceuticals is not included in the S&P 500 index

Is X4 Pharmaceuticals in the NASDAQ 100?

No, X4 Pharmaceuticals is not included in the NASDAQ 100 index

Is X4 Pharmaceuticals in the Dow Jones?

No, X4 Pharmaceuticals is not included in the Dow Jones index

When was X4 Pharmaceuticals's last earnings report?

X4 Pharmaceuticals's most recent earnings report was on Mar 25, 2025

When does X4 Pharmaceuticals report earnings?

The next expected earnings date for X4 Pharmaceuticals is May 7, 2025

Should I buy X4 Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page